A PEG-peptide conjugate based on an amyloid β peptide fragment was synthesized. The formed amyloid protofibril-like aggregates induced intramolecular FRET. It proved to be useful as a bioprobe to evaluate the inhibitory effect of organic molecules toward amyloid fibrillization.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/c0cc05668e | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cyclodextrin-Induced Suppression of PEG Crystallization from the Melt in a PEG-Peptide Conjugate.
Chembiochem
October 2024
DUBBLE-CRG @ ESRF, CS40220, The European Synchrotron, 71, Avenue des Martyrs, 38043, Grenoble Cedex 9, France.
The influence of alpha-cyclodextrin (αCD) on PEG crystallization is examined for a peptide-PEG conjugate, YYKLVFF-PEG3k comprising an amyloid peptide YYKLVFF linked to PEG with molar mass 3 kg mol. Remarkably, differential scanning calorimetry (DSC) and simultaneous synchrotron small-angle/wide-angle X-ray scattering (SAXS/WAXS) show that crystallization of PEG is suppressed by αCD, provided that the cyclodextrin content is sufficient. A hexagonal mesophase is formed instead.
View Article and Find Full Text PDFA Protease-Responsive Polymer/Peptide Conjugate and Reversible Assembly of Silver Clusters for the Detection of Enzymatic Activity.
ACS Nano
September 2023
Department of Nano and Chemical Engineering, University of California, San Diego, La Jolla, California 92093, United States.
Article Synopsis
- - The study explores how silver nanoparticles (AgNPs) can reversibly aggregate when combined with a specific peptide and polyethylene glycol (PEG), with optimal dissociation occurring at a PEG molecular weight of 1 kDa, significantly impacted by the peptide sequence and PEG size.
- - This dissociation technique is effective in various complex biofluids, maintaining stability under different conditions, such as drying and rehydration, freezing and thawing, or prolonged light exposure.
- - A novel PEG-peptide hybrid molecule was created to specifically detect the RgpB protease linked to periodontitis and chronic diseases, achieving a 40% detection rate in gingival crevicular fluid without false negatives, which demonstrates the method's potential
Di-Arginine Additives for Dissociation of Gold Nanoparticle Aggregates: A Matrix-Insensitive Approach with Applications in Protease Detection.
ACS Appl Mater Interfaces
November 2022
Department of NanoEngineering, University of California, San Diego, La Jolla, California92093, United States.
We report the reversible aggregation of gold nanoparticles (AuNPs) assemblies via a di-arginine peptide additive and thiolated PEGs (HS-PEGs). The AuNPs were first aggregated by attractive forces between the citrate-capped surface and the arginine side chains. We found that the HS-PEG thiol group has a higher affinity for the AuNP surface, thus leading to redispersion and colloidal stability.
View Article and Find Full Text PDFInvestigation on the Interactions between Self-Assembled β-Sheet Peptide Nanofibers and Model Cell Membranes.
Int J Mol Sci
December 2020
Faculty of Molecular Chemistry and Engineering, Kyoto Institute of Technology, Gosyokaido-cho, Matsugasaki, Sakyo-ku, Kyoto 606-8585, Japan.
Self-assembled peptide nanofibers (NFs) obtained from β-sheet peptides conjugated with drugs, including antigenic peptides, have recently attracted significant attention. However, extensive studies on the interactions of β-sheet peptide NFs with model cell membranes have not been reported. In this study, we investigated the interactions between three types of NFs, composed of PEG-peptide conjugates with different ethylene glycol (EG) lengths (6-, 12- and 24-mer), and dipalmitoylphosphatidylcholine (DPPC) Langmuir membranes.
View Article and Find Full Text PDFPreparation of Peptide and Recombinant Tissue Plasminogen Activator Conjugated Poly(Lactic-Co-Glycolic Acid) (PLGA) Magnetic Nanoparticles for Dual Targeted Thrombolytic Therapy.
Int J Mol Sci
April 2020
Department of Chemical and Materials and Materials Engineering, Chang Gung University, Kwei-San, Taoyuan 33302, Taiwan.
Recombinant tissue plasminogen activator (rtPA) is the only thrombolytic agent that has been approved by the FDA for treatment of ischemic stroke. However, a high dose intravenous infusion is required to maintain effective drug concentration, owing to the short half-life of the thrombolytic drug, whereas a momentous limitation is the risk of bleeding. We envision a dual targeted strategy for rtPA delivery will be feasible to minimize the required dose of rtPA for treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!